CLINICAL_TRIALS
trial_result
· 2021-03-17
Clinical Trial Update: Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML [Phase 2]
Summary
Phase 2 trial update evaluating Standard of Care with or without Midostaurin to prevent relapse after stem cell transplant in FLT3-ITD mutated AML.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Novartis Pharmaceuticals | Conditions: Acute Myeloid Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2021-03-17